Is AO a Blood Type or Just a Genotype?

AO is a genotype, not a blood type. If your DNA results say you are AO, your blood type is A. Standard blood typing recognizes four groups (A, B, AB, and O) based on the antigens present on red blood cells, and a person carrying one A allele and one O allele produces A antigen just the same as someone carrying two A alleles. The reason AO has started to confuse people is that direct-to-consumer genetic tests now report what used to stay hidden in the genetics lab, and the distinction between what your genes say and what your blood cells actually display is less obvious than it sounds.

Why Your Blood Test Says A, Not AO

When a hospital or blood bank determines your blood type, they mix your red blood cells with antibodies that react to specific sugar molecules on the cell surface. If the anti-A antibody causes clumping, you have A antigen and you are typed as blood group A. The test does not care whether the instructions for that antigen came from one chromosome or both. Whether you inherited an A allele from each parent (AA) or an A allele from one parent and an O allele from the other (AO), your red blood cells carry A antigen either way, and the lab result is the same: type A.

The O allele, in most cases, is a nonfunctional version of the ABO gene. The most common O allele carries a single missing nucleotide early in its coding sequence, which scrambles the rest of the instructions and prevents the gene from producing a working enzyme. Without that enzyme, no A or B sugar gets added to the cell surface. Because the A allele in an AO person still produces a fully functional enzyme, A antigen appears on the red blood cells, and the O allele’s silence goes unnoticed by serology. A large genotype-phenotype comparison study found that AO and AA genotypes showed greater than 94% concordance with serological blood group A, while OO genotype samples matched blood group O 99.3% of the time.¹

Where AO Shows Up and Why People See It Now

For most of the twentieth century, the only people who ever encountered a designation like “AO” were genetics students working through inheritance problems. Blood banks reported phenotypes: A, B, AB, O. That changed when consumer DNA testing became mainstream. Companies that analyze your saliva or cheek swab can look directly at the ABO gene and tell you which alleles you carry. A handful of well-known single-nucleotide variants are used for this: one flags the common O1 deletion, another identifies the O2 variant, a third distinguishes B from A, and a fourth picks out the A2 subgroup.² The result is that millions of people now see “AO” or “BO” on a screen without context explaining that this is a genotype, not a blood type in the clinical sense.

DNA-based blood group typing does have clinical applications. It provides more comprehensive information than serology alone and is easier to standardize across laboratories.³ But in transfusion medicine, what matters at the bedside is the phenotype: which antigens are present on the red cells and which antibodies are circulating in the plasma. The genotype is a tool for getting at that answer more reliably in tricky situations, not a replacement for it.

When Genotyping Beats a Standard Blood Test

Routine serological typing works well for most people, but certain clinical situations make it unreliable. Patients who receive frequent transfusions, such as those with thalassemia or sickle cell disease, end up with a mix of their own red blood cells and donor cells circulating at the same time. That mixed population can give confusing results on a standard antibody test. In these patients, molecular genotyping can reliably determine the person’s actual antigen profile and help blood banks select better-matched units, reducing the risk of transfusion reactions.⁴ Studies comparing serological and molecular methods in sickle cell patients have found discrepancies between the two approaches in a meaningful fraction of cases.⁵

Genotyping also matters when a person’s blood appears to tell a different story than expected. Rarely, unusual mutations in the ABO gene can knock out antigen expression even though one allele should theoretically be functional. One documented example involved a 24-base-pair deletion in the ABO gene that disrupted normal processing of the gene’s instructions. Family members who inherited one copy of this mutated allele alongside a normal A allele failed to express A antigen on their red cells, making them look like group O by standard typing despite carrying an A allele.⁶ Cases like this are rare, but they illustrate why genotyping sometimes reveals a reality that serology misses.

What AO Means for Your Children

This is probably the most practical reason to care about whether you are AO or AA. If you are blood type A and your partner is blood type O, the children you can have depend entirely on your hidden allele. An AA parent paired with an OO parent will produce children who are all AO, meaning every child will be blood type A. An AO parent paired with an OO parent, on the other hand, has roughly a 50-50 chance of passing along either the A or the O allele, so about half the children would be type A (AO) and the other half would be type O (OO).

This is the scenario that sometimes causes confusion in families. A couple where one parent is type A and the other is type O might have a child who is type O, leading to puzzled questions about how that is possible. The answer is straightforward once you know the type-A parent is AO rather than AA. The child simply inherited the O allele from both parents. It is entirely normal and does not suggest anything unusual about parentage, though before genotyping was widely available, it occasionally led to awkward conversations.

A Subgroups and Antigen Density

Not all type-A blood is identical, and this is one place where the AO distinction can ripple into something more tangible. The two main subgroups of A are called A1 and A2. Roughly 80% of type-A individuals are A1 and the rest are A2. The difference between them lies in how densely the A antigen is packed onto the red blood cell surface. A1 cells have substantially more A antigen than A2 cells, and the structural details of the sugar chains differ between them. Research on the chemical basis of these differences has shown that on A2 red cells, certain sugar structures remain largely un-glycosylated with the terminal A sugar, meaning fewer copies of the full A antigen are present.⁷

This matters because A2 individuals, especially those who are A2O, can occasionally produce antibodies against A1 cells, which may complicate both transfusion and organ transplantation. In solid-organ transplantation, A2 kidneys are sometimes considered compatible with group O or group B recipients because the antigen load is low enough to avoid strong rejection. The genotype, including whether someone is A2O versus A2A2, can inform these decisions. For everyday blood typing and donation, though, A1 and A2 are both type A and are treated accordingly.

The Bombay Phenotype and Other Genetic Twists

There are situations where a person carries a perfectly functional A (or B) allele but still types as O on a blood test. The most famous of these is the Bombay phenotype. The A and B enzymes work by adding specific sugar molecules to a precursor structure called the H antigen. If the H antigen is not present in the first place, the A and B enzymes have nothing to work with, and no A or B antigen appears on the cell surface. The Bombay phenotype results from inactivating mutations in the FUT1 gene, which encodes the enzyme responsible for building the H antigen.⁸ A person with Bombay phenotype might be AO, AA, or even AB by genotype, yet their red cells display none of these antigens. Their serology reads as O, but not the same O as someone with OO genotype: Bombay individuals lack the H antigen too, making them incompatible with standard group O blood.

Bombay phenotype is extremely rare in most populations but occurs at higher rates in certain communities in South Asia. It is a dramatic example of how the blood type on your medical chart and the alleles in your genome can tell different stories.

Cis-AB and Other Rare Variants

Another genetic curiosity that scrambles expectations is cis-AB. In normal ABO genetics, the A and B alleles sit on different chromosomes, one inherited from each parent. Cis-AB is a rare variant in which a single mutated allele produces an enzyme with both A and B activity. Both A and B antigens end up on the red blood cells, but they came from the same parent rather than one from each.⁹ The practical consequence is bizarre-looking inheritance patterns. Two parents who are both type O, for instance, could have a child who appears to be AB if one parent carries a cis-AB allele paired with O. Cis-AB was first identified because of exactly this kind of “impossible” family typing result, and it remains a headache for blood banks when it turns up unexpectedly.

Variants like cis-AB and the Bombay phenotype underscore a broader point: the four neat categories of A, B, AB, and O are a simplification that works almost all the time but not literally always. Genotyping peels back that simplification and reveals a messier, richer landscape underneath.

When Disease Changes Your Blood Type

Your ABO genotype is fixed for life, but your phenotype is not always as stable as you would expect. In certain blood cancers, particularly acute myeloid leukemia, the disease can suppress the expression of ABO antigens on red blood cells. A patient who has always been type A might suddenly test as type O during the active phase of their leukemia, then revert to type A when they achieve remission.¹⁰ Case reports have documented this pattern repeatedly: initial workups find a patient to be group O, but once chemotherapy brings the leukemia under control, A antigen reappears on the cells, revealing the patient’s true underlying type.¹¹

This creates obvious challenges for transfusion safety. If the blood bank types a leukemia patient during active disease and sees group O, they will issue group O blood. That is safe in the moment, but once the patient’s own antigens return, the clinical team needs to recognize that the patient’s “real” type is A and adjust accordingly. Genotyping the patient at diagnosis can prevent this confusion entirely, because the DNA does not change even when antigen expression on the cell surface temporarily vanishes.¹²

AO Versus AA and Health Risks

A natural follow-up question is whether being AO carries different health implications from being AA. The short answer is that for most known disease associations with ABO, what matters is the phenotype, not the specific genotype. The classic example is the link between non-O blood types and higher levels of von Willebrand factor, a clotting protein. People with blood types A, B, and AB have higher circulating levels of this protein than people with type O, and that gap widens with age. Research has shown that the age-related increase in von Willebrand factor and factor VIII is significantly steeper in non-O individuals, with the mean difference in von Willebrand factor levels between non-O and O subjects growing from a modest gap in younger adults to a much larger one in older adults.¹³ This elevated clotting factor is linked to a modestly higher risk of venous blood clots and cardiovascular events in non-O individuals.

But this research groups all type-A people together regardless of whether they are AA or AO. There is some emerging interest in whether a “gene dose” effect exists, where AA individuals might have slightly higher antigen density and therefore slightly different risk profiles compared to AO individuals. Evidence on this point remains thin. One area where genotype-level data has proven informative is malaria research, where AO genotype has been distinguished from AA in studies of how different blood group genotypes relate to disease severity, and the concordance between genotype and phenotype has been confirmed to be high enough to treat them interchangeably in most analyses.¹ For now, if your concern is cardiovascular risk or clotting, knowing you are type A is the relevant clinical fact; knowing you are AO rather than AA does not change any medical recommendation.

ABO Antigens Beyond Red Blood Cells

One common misconception is that blood type antigens exist only on red blood cells. In reality, A, B, and H antigens are expressed in many tissues throughout the body, including the lining of the gut, the respiratory tract, and various secretions. Whether these antigens show up in your saliva, mucus, and other body fluids depends on a separate gene called FUT2. People who carry at least one functional copy of FUT2 are called “secretors” and do express ABO antigens in their secretions; those with two nonfunctional copies are “non-secretors” and do not.¹⁴ Roughly 20% of people of European descent are non-secretors.

Secretor status interacts with ABO type in ways that affect susceptibility to certain infections. The FUT2 gene has been investigated as a genetic marker for susceptibility to a range of infectious diseases, because the presence or absence of ABO antigens on mucosal surfaces influences which pathogens can latch onto those surfaces.¹⁵ This is a layer of complexity that sits on top of ABO blood type and has nothing to do with whether you are AO versus AA. A non-secretor who is AO and a non-secretor who is AA would have the same mucosal antigen profile: none. The FUT2 gene acts as an independent switch, so secretor status is worth being aware of as a separate factor from blood type.

Chimerism and Mixed Blood Types

There is one genuinely unusual situation in which a person can carry A, B, and O alleles simultaneously. Tetragametic chimerism occurs when two fraternal twin embryos fuse very early in development, resulting in a single individual whose body contains two genetically distinct cell lines. A documented case involved a healthy woman whose red blood cells showed mixed-field agglutination during routine ABO testing, meaning some cells reacted with anti-A, some with anti-B, and some with neither. Molecular typing confirmed that she carried A, B, and O alleles.¹⁶ Her blood was essentially two populations of red cells coexisting in the same circulatory system, each with a different ABO type. Chimerism is exceedingly rare, but it is one more reason genotyping sometimes tells a different story than serology.

Why ABO Diversity Persists at All

Stepping back from the clinical details, a reasonable question is why humans have A, B, and O alleles in the first place. The ABO polymorphism is ancient. Comparative genetic studies have demonstrated that the A and B blood groups represent a trans-species polymorphism maintained under balancing selection for tens of millions of years, predating the split between humans and Old World monkeys.¹⁷ That is an extraordinarily long time for natural selection to keep multiple versions of a gene in play rather than driving one to fixation.

The leading explanation involves pathogens. Because ABO antigens are displayed on gut and mucosal surfaces, bacteria and other infectious organisms can evolve to exploit whichever antigen is most common in a population. This creates a selective advantage for rarer alleles: when most people in a population are type A, pathogens adapted to A antigen thrive, and individuals carrying B or O gain a survival edge. Over time, this frequency-dependent dynamic keeps all three alleles circulating.¹⁸ Additional modeling has pointed to gut pathogens specifically as a likely driver of this co-evolutionary arms race.¹⁹ The O allele, rather than being an afterthought or a broken gene, may confer its own distinct advantages against certain infections, which is why it remains the most common allele globally despite producing no antigen at all.

Enzymatic Conversion and Universal Blood

One of the more ambitious lines of research in transfusion science takes the AO distinction in an unexpected direction: if the only difference between type A and type O red blood cells is a single sugar molecule on the surface, what if you could simply shave that sugar off? Researchers have been developing enzymes, glycosidases, capable of removing the A and B sugars from donated red blood cells, effectively converting them to type O cells that could be transfused to anyone.²⁰ The concept is straightforward: the A transferase enzyme encoded by the ABO gene adds a specific sugar to build the A antigen, so a corresponding enzyme that clips that sugar off should undo the work and produce a functionally O-type cell.

Progress has been real but slow. The challenge lies in removing every last molecule of A or B antigen from every red blood cell in a unit of donated blood, because even trace amounts of residual antigen could trigger a transfusion reaction in a type-O recipient. The enzymes need to be efficient enough for industrial-scale blood processing and safe enough that no residual enzyme activity remains in the final product. If this technology matures, the distinction between AO and OO would become moot in the donation context: all blood could be made functionally universal. Until then, AO remains an invisible genotype behind a perfectly normal type-A blood donation.